Abstract. Drug concentrations that would prolong repolarization parameters by 10%, including action potential duration (APD 90 , APD 30 -90 ), in in vitro assays using guinea-pig papillary muscle and QTc intervals in in vivo assays using conscious dogs, conscious monkeys, and anesthetized dogs were compared. Although, both the in vitro and in vivo assays showed concentrationdependent responses for compounds that have been classified as torsadogenic in humans, only a weak correlation in EC 10 values was observed between the in vitro and in vivo assays. Among the in vivo QT assays, the EC 10 values obtained from conscious dogs, conscious monkeys, and anesthetized dogs correlated well with each other, but the EC 10 values in monkeys were somewhat lower in comparison to those in dogs. When in vivo QT assay EC 10 values were compared to the respective human effective therapeutic plasma concentration (ETPC), the ratios of EC 10 values to ETPCs were less than 20 for most torsadogenic compounds. In conclusion, the relationships between the extent of QTc interval prolongation and the concentration of drugs was highly consistent among the three in vivo models, suggesting that the ratios of EC 10 values in in vivo QT assays are useful for estimating the safety margin of drugs that prolong the QTc interval.
Introduction
Prolongation of the QT interval on electrocardiograms (ECG) is considered to reflect a delay in ventricular repolarization and is known to be a characteristic of familial and acquired long QT syndrome (LQTS) (1, 2) . Since drugs are known to be one of the causes of acquired LQTS and associated ventricular arrhythmias such as torsade de pointes (TdP) (3, 4) , drug-induced QT interval prolongation is an important issue that must be addressed during non-clinical and clinical safety evaluations for new drug development (2 -5) . Several nonantiarrhythmic drugs, such as the gastrointestinal prokinetic agent cisapride and the nonsedating antihistamines astemizole and terfenadine, have been withdrawn from the market due to this unexpected severe adverse effect, albeit at low incidence (6) . Since LQTS has become a major regulatory concern, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) S7B is currently developing guidelines for drugs that may affect the QT interval (7) .
Many in vitro and in vivo non-clinical experimental models for detecting the effect of drugs on QT interval or identifying the mechanism behind proarrhythmic effects have been reported (3, 4, 8, 9 ). An in vitro assay on the K + current through a channel encoded by a human ether-a-go-go-related gene (hERG) , that is, a rapid component of the delayed rectifier K + current (I Kr ), as well as in vitro action potential assays using the papillary muscle of guinea pigs or Purkinje fibers from dogs or rabbits and in vivo QT assays using conscious freemoving or anesthetized non-rodent animals have generally been used to evaluate the proarrhythmic potential of new chemical entities in cardiovascular safety pharmacology studies. Although these studies are recommended in the ICH S7B guideline, there are very few reports that validate these experimental models systematically. In order to construct a database that is useful for evaluating non-clinical results of new chemical entities and to support ICH S7B guideline development, the collaborative project "QT Interval Prolongation: Project for Database Construction (QT PRODACT)," which was organized by the Japan Pharmaceutical Manufacturers Association (JPMA), has studied a total of 21 compounds using in vitro action potential assays and in vivo QT assays involving conscious beagle dogs, conscious cynomolgus monkeys, and anesthetized dogs. Thirty-nine pharmaceutical companies belonging to the JPMA and 7 contract research laboratory organizations (CROs) in Japan participated in this project. Each experimental model was tested by multiple facilities in accordance with a standard protocol prepared by the QT PRODACT, allowing these data to be collected systematically with similar inclusion criteria, exclusion criteria, and evaluation methods. The details of the results of each experimental model were reported separately (10 -13) .
Recently, it has been reported that the ratio of the hERG/ I Kr assay IC 50 values to the C max value for humans given an effective therapeutic dose (hereafter referred to as ETPC) is useful for assessing whether or not the compound causes potential QT-interval-prolongationrelated arrhythmias in humans. Only isolated instances of TdP in humans have been reported for ratios greater than 30-fold (6). A similar conclusion based on a smaller set of compounds was reported by Webster et al. (14) . Regarding the in vitro action potential and in vivo QT assays, only an obscure understanding of the relationship between ETPC and the compound concentration that causes prolongation of action potential duration (APD) or corrected QT (QTc) interval exists for the experimental models. The ICH S7B guideline recommends that the integrated risk assessment should also take the relationship between the exposures associated with the effect on repolarization and those eliciting a primary pharmacodynamic effect into consideration for the nonclinical test species as well as the proposed therapeutic effective concentration in humans (7) .
The purpose of the studies described in this article are twofold: 1) Based on the QT PRODACT data, we calculated the plasma concentrations of the tested drugs that would prolong the QTc interval by 10% by using in vivo assays in conscious dogs, conscious monkeys, and anesthetized dogs. 2) We determined the in vitro concentrations of the tested drugs that would prolong APD 30 -90 (triangulation parameter) and APD 90 by 10% (EC 10 ) for in vitro action potential assays in guinea-pig papillary muscle to compare the EC 10 values among the models. Furthermore, non-clinical data obtained from the QT PRODACT and clinical ETPC from the literature are compared to investigate the relationship between the two.
This study was not intended to evaluate the safety of each compound in humans, but the results of each compound under the experimental conditions used in this study are presented. The safety evaluation of each compound should integrate non-clinical, clinical, and other relevant information. Therefore, it is impossible to evaluate the safety of each compound based solely on the results obtained in this study.
Materials and Methods
Details of the methods and results for each assay are reported separately (10 -13) .
Compounds
A total of 21 test compounds used in the QT PRODACT are listed in Table 1 . The eleven positive compounds are known to induce ventricular tachycardic events like TdP and are associated with excessive prolongation of the QT interval in humans. The ten negative compounds are thought to not have effects like the those of the positive compounds. As this is a multisite study based on a standard protocol established by the QT PRODACT, dl-sotalol was also tested as the common positive compound for all assays at all facilities in order to determine inter-facility variability and check the detection sensitivity of each facility's assay system. E-4031 and MK-499 were kindly supplied by Eisai Co., Ltd. (Tokyo) and Merck & Co., Inc. (Rahway, NJ, USA), respectively. Other compounds were commercially available chemical compounds or drug products.
Animals
Male Hartley guinea pigs (234 -503 g), male beagle dogs (8 -21 months, 7 -15.5 kg), and cynomolgus monkeys (3 -7 kg) were used. Experimental protocols in each testing facility followed the guidelines set by the Committee for Experiments on Animals at each testing facility and the Guiding Principles for the Care and Use of Laboratory Animals approved by The Japanese Pharmacology Society.
Assay systems and parameters
In the QT PRODACT, the effects of positive and negative compounds on QT interval were examined by using 4 assay systems that included an in vitro action potential assay using guinea-pig papillary muscle as well as three in vivo QT assays involving conscious dogs, conscious monkeys, and anesthetized dogs.
Source of the data
All the studies were conducted in accordance with the standard protocols prepared by the QT PRODACT. Details of these standard protocols have been described in other related articles (10 -13) . The protocol outline for each assay system and the approach of data analysis used in this article are as follows:
In vitro action potential assay using guinea-pig papillary muscle (10) : Papillary muscles dissected from the right ventricles of guinea pigs were fixed in a chamber, superfused with Tyrode solution at 37°C, and aerated with a gas mixture of 95% O 2 / 5% CO 2 . The action potential was recorded via a glass microelectrode using an action potential recording / analysis system. Effects of the test compounds on action potential parameters were evaluated using the data before and after the 30-min application period. Each group was comprised of six specimens. The effects of dl-sotalol at a concentration of 30 µmol / L was also examined to investigate inter-facility variability.
APD In vitro action potential assay used only.
b)
Common positive compound. *: Statistically significant difference from vehicle control (P<0.05). # : Increases in APD90 or APD30-90 of more than 10% were observed for at least one concentration level. [ ]: Changes in APD90 or APD30 -90 of more than 10% were not observed at the highest concentration level tested.
was calculated using log [concentration]-logit [% change] linear-regression analysis.
In vivo QT assays using conscious dogs (11), conscious monkeys (12) , and anesthetized dogs (13) : For the in vivo QT assays involving conscious animals, three or four males (beagle dogs, cynomolgus monkeys), each implanted with telemetry transmitters for measurement of arterial mean blood pressure, heart rate, and lead II ECG, were used to evaluate each test compound at each facility. The vehicle and 3 doses of each compound were administered orally to animals in either a Latin square or dose-escalation design with sufficient intervals that was decided based on pharmacokinetic and / or pharmacodynamic properties of each test compound. The effects of dl-sotalol were examined to determine inter-facility variability.
For the in vivo QT assay with anesthetized dogs, three or four male beagle dogs were anesthetized with isoflurane vaporized with oxygen and N 2 O (2:3). A catheter for measurement of blood pressure was inserted through the femoral artery and positioned in the abdominal aorta. The surface lead II ECG was obtained from the limb electrodes. Test compound was administered intravenously in a series of 3 ascending dose levels cumulatively following vehicle administration. Each dose was infused over 10 min at 30-min intervals. Separately, before the start of the experiments, dl-sotalol was used to investigate inter-facility variability. The vehicle was also infused 4 times over 120-min period to confirm the stability of the assay system.
The QT interval was corrected using Fridericia's formula (QTc = QT/ RR ) for monkeys. Furthermore, in order to confirm systemic exposure, blood samples were collected after the ECG analysis time points, after which plasma concentrations were measured using a validated method.
In all in vivo QT assays, percent changes from the vehicle average baseline values were calculated individually at each assay point in all groups including the vehicle. The maximum difference in prolongation for the mean percent changes between each dose and timematched vehicle was used to calculate the EC 10 and ED 10 values. EC 10 and ED 10 values, which are, respectively, the plasma compound concentration and the dose level that caused an approximately 10% increase in the QTc interval of the animals, were calculated using linear-regression analysis.
The EC 10 unbound value was defined as the unbound / free plasma concentration that produced a 10% QTc interval prolongation. The value was calculated from the plasma protein binding and EC 10 total data.
The following data were collected from the literature (6, 17, 22 -26) .
Data analyses
The EC 10 values were compared between the in vitro and in vivo experimental models. The correlation coefficient (R 2 value) was calculated using commercial graphic software.
To determine the safety margin relative to the EC 10 values, the ratios of the EC 10 values for the in vivo QT assays to human ETPC (EC 10 total / ETPC total and EC 10 unbound / ETPC unbound ) were calculated.
Results

EC 10 or ED 10 values for each assay system
In vitro action potential assay using guinea-pig papillary muscles: The EC 10 values for APD 90 and APD 30 -90 are shown in Table 1 . The IC 50 values of the hERG/ I Kr assay gathered through a literature survey are also shown in Table 1 . A standard positive compound, dl-sotalol, at a concentration of 30 µmol / L significantly increased both APD 90 and APD 30 -90 by more than 10% at all testing facilities (27) . The inter-facility variability was much less than the intra-facility variability, such as that due to individual differences among animals (27) .
Seven of 11 positive compounds increased APD 90 by more than 10%. The EC 10 values were then calculated. Flecainide, a negative compound, significantly increased APD 90 , although the change was within 10% at the highest concentration tested. The other compounds did not influence APD 90 .
As for APD 30 -90 , the I K index (10, 28) , showed that 9 of 11 positive compounds and 2 of 10 negative compounds, all of which are known to have an I Kr -blocking action, significantly increased APD 30 -90 by more than 10%. Their EC 10 values were then calculated. Pimozide and dl-propranolol significantly increased APD 30 -90 , although the change was within 10% at the highest concentration tested. The other compounds did not influence APD 30 -90 . Among the compounds with I Kr blocking action, E-4031 most potently increased ADP 30 -90 , with the EC 10 value of 0.007 µmol / L. For some antiarrhythmic compounds such as E-4031, disopyramide, and MK-499, EC 10 values were almost similar to the hERG / I Kr assay IC 50 values.
In vivo QT assays: The ED 10 and EC 10 values for the QTc interval are shown in Table 2 . dl-Sotalol caused an increase in QTc interval of more than 10% at doses of 10 mg / kg (p.o.) for conscious dogs, 5 mg / kg (p.o.) for conscious monkeys, and 3 mg / kg (i.v.) for anesthetized dogs at all testing facilities (13, 29) . The ranges of the percent of QTc interval prolongation induced by dlsotalol for conscious dogs, conscious monkeys, and anesthetized dogs are 11% -18%, 11% -20%, and 16% -47%, respectively.
In conscious and anesthetized dogs, all positive compounds tested caused a QTc interval prolongation of more than 10%, which is statistically significant. Although one negative compound, nifedipine, showed an 11% increase in QTc interval (statistically significant), the EC 10 value was not calculated because this change was considered to be due to insufficient QT interval correction by heart rate (11). In conscious monkeys, most positive compounds caused a QTc interval prolongation of greater than 10% (both / and not), which was statistically significant. However, terfenadine and haloperidol caused no significant prolongation of the QTc interval, probably due to low the plasma concentrations of these compounds.
E-4031 and MK-499, pure I Kr inhibitors, produced marked QTc interval prolongations in all these models. For class III antiarrhythmic compounds, the EC 10 total values obtained from the in vivo QT assays were almost similar to the ETPC total for humans (Tables 1 and 2 (Fig. 1) . When the EC 10 values for APD 30 -90 were compared with those for EC 10 unbound for the in vivo QT assays with conscious or anesthetized dogs, only weak correlations were observed. The R 2 value for conscious dogs was 0.281 and for anesthetized dogs, 0.354. There was no correlation between the EC 10 value for APD 90 and the EC 10 unbound value for the in vivo QT assays (R 2 = <0.149) in either of the dog models. Furthermore, the EC 10 total and EC 10 unbound (data not shown) values for the in vivo QT assay involving conscious monkeys were similar to those for the in vivo QT assays involving conscious dogs and anesthetized dogs, respectively.
Comparison of EC 10 total values between conscious dogs and conscious monkeys: When the EC 10 total values of conscious dogs and conscious monkeys were compared, there was a very good correlation (R 2 = 0.947, Fig. 2) . Except for thioridazine, the EC 10 total values were smaller for monkeys. There was a large difference in the incidence of ventricular arrhythmias between the two models. Ventricular arrhythmias, such as premature ventricular contraction and TdP, were observed in astemizole-, cisapride-, and dl-sotalol-treated conscious monkeys, whereas no arrhythmias were noted in conscious dogs even though the plasma concentration levels were comparable.
Comparison of EC 10 total values between conscious dogs and anesthetized dogs: There was a good correlation of the EC 10 total values between conscious dogs and anesthetized dogs (R 2 = 0.816, Fig. 2 ). Ventricular arrhythmias were observed in haloperidol-treated anesthetized dogs, but not in conscious dogs, even though the plasma exposure levels were comparable.
Safety margin relative to ETPC values
The human ETPC total and ETPC unbound values found in the literature are shown in Table 1 . When the ETPC total values for humans were compared with the QTcinterval-prolongation EC 10 total values for in vivo QT assays, the ratios of EC 10 total values to the human ETPC total were less than 20 (Fig. 3, Table 2 ) for all positive compounds, except for terfenadine, in the anesthetized dog model. For terfenadine, the ratio was 123-fold in anesthetized dogs, while that in conscious animals was less than 20-fold.
For antiarrhythmic compounds such as E-4031, MK-499, and quinidine, the ratios (EC 10 total / ETPC total , EC 10 unbound / ETPC unbound ) were less than 10.
Discussion
QT PRODACT has studied 11 positive compounds and 10 negative compounds. As the testing facilities were different for each test compound QT PRODACT studied, we used dl-sotalol as a standard positive compound in all facilities. dl-Sotalol was selected for the following reasons: low plasma protein binding (6) , high bioavailability, no CYP enzyme metabolites, its QT interval prolongation property has been well-documented in the literature (2 -4, 6, 8) , and it is a readily available commercial product. In all testing facilities, dl-sotalol at a concentration of 30 µmol / L significantly increased APD 90 and APD 30 -90 in in vitro action potential assays (27) . In in vivo QT assays, dl-sotalol significantly prolonged QTc intervals at doses of 10 mg / kg (p.o.) in conscious dogs, 5 mg / kg (p.o.) in conscious monkeys, and 3 mg / kg (i.v.) in anesthetized dogs (13, 29) .
We calculated the ratios between the EC 10 values in the animal models and ETPC in humans to compare drug-induced QT interval prolongation in the animal models. We then used these values to determine a putative safety margin relative to the EC 10 value.
We used the EC 10 value to calculate the safety margin because the maximum percent changes induced by the test compounds were approximately 20% -30% in each assay system, and an approximately 10% change usually yields a statistically significant difference from the vehicle control.
Comparison of animal models for drug-induced QT interval prolongation
For the in vitro action potential assay using guinea-pig papillary muscles, APD 30 -90 has proved to be a useful marker for detecting I K blocking action (10, 28) . The I Kr blocking action caused by multi-channel blockers such as bepridil was detected by APD 30 -90 , but not APD 90 . Non-I Kr -blocking compounds did not influence APD 90 or APD 30 -90 , even at very high concentrations that exceed the ETPC in humans. However, the EC 10 values for APD 30 -90 do not correlate with the IC 50 values for the hERG / I Kr assays.
In in vivo QT assays done using conscious and anesthetized dogs, all positive compounds tested caused significant QTc interval prolongation. However, in conscious monkeys, haloperidol, pimozide, cisapride, terfenadine, and thioridazine caused no clear QTc interval prolongation, probably due to tachycardia, low plasma concentration, and so on (12) .
With the exception of nifedipine in conscious dogs, negative compounds did not influence the QTc interval in in vivo QT assays. In nifedipine-treated conscious dogs, increased heart rate was observed, indicating that the QT interval correction may be insufficient to compensate for the rapid heart rate (11).
Given these results, it is clear that the sensitivity and specificity of the safety pharmacology studies (i.e., in vitro action potential assay and in vivo QT assays) were sufficient to predict a potential risk for humans (10 -13) . In each assay system, however, some compounds yielded a false positive or false negative. Therefore, it is necessary to use a combination of two or more assay systems together with the pharmacodynamic and/ or pharmacokinetics profiles of new chemical entities. The ICH S7B guideline also states that other information on the compound should also be taken into consideration for a true integrated risk assessment of the potential for drug-induced QT interval prolongation.
When the EC 10 values of the APD 30 -90 in the in vitro action potential assay were compared with the EC 10 unbound values (unbound / free plasma concentration) of the in vivo QT assays, a weak correlation between them was detected. However, no correlation was observed between the APD 90 EC 10 values and those obtained from the in vivo QT assays. There was no clear correlation between the APD 30 -90 EC 10 values and the hERG/ I Kr assay IC 50 values. On the other hand, it has been reported that the hERG / I Kr assay IC 50 values do correlate well with the free plasma concentrations associated with QT interval prolongation / TdP in animals (14) . As mentioned above, there was only a weak correlation between the APD 30 -90 EC 10 values and the in vivo QT assay EC 10 unbound . The reason is that the APD 30 -90 EC 10 values for some compounds like astemizole were very different from the in vivo QT assay EC 10 unbound values. Namely, the APD 30 -90 EC 10 values were higher than the in vivo QT assay EC 10 unbound as well as the hERG / I Kr assay IC 50 values. Although the reason for this was not clear, differences in the compound concentration that penetrated into the tissue or cells may be an issue. If the penetration of compound into tissue is not a consideration, it may be possible to use the APD 30 -90 instead of the hERG / I Kr assay.
In the in vivo QT assays, there were no differences in the ED 10 values between conscious dogs and conscious monkeys. Furthermore, there was a good correlation between conscious dogs and conscious monkeys when EC 10 total values of the two models were compared. On the other hand, except for thioridazine, the EC 10 values for conscious monkeys were lower than that for conscious dogs. In addition, the ventricular arrhythmias seen after the dosing of some positive compounds were observed in conscious monkeys, but not in conscious dogs. Monkeys may therefore be sensitive to arrhythmogenic compounds or I Kr blockers, but dogs may not be. Alhough the reason for this is not clear, species differences may be involved.
In the in vivo QT assay using anesthetized dogs, all positive compounds tested caused significant QTc interval prolongation, and none of the negative compounds influenced the QTc interval. Therefore, the sensitivity and specificity of in vivo QT assays using anesthetized dogs is superior to those using conscious dogs or conscious monkeys for predicting whether a drug will cause QT interval prolongation in humans. There was a good correlation between the EC 10 total values of conscious dogs and anesthetized dogs when the two were compared; in fact, they were almost the same. The use of the latter assay system has several benefits, including the following: no implantation surgery is necessary for the telemetry devices, a shorter experiment period compared to the telemetry assay, experimental conditions do not influence the result, and ECG parameters are easily analyzed, and so forth. For anesthetized dogs, however, a separate study may be needed to evaluate drug disposition. Therefore, when studying the effects of new chemical entities on the QT interval, it is important to select the animal model with careful consideration of the animal model's features, compound profile, study purpose, and so on.
It has been reported that unbound / free plasma concentrations associated with QT prolongation / TdP in the clinical setting correlates well with that of in vivo non-clinical studies (14) . For antiarrhythmic compounds such as E-4031, MK-499, and quinidine, the ETPC in humans is almost equal to the plasma concentration associated with QT interval prolongation / TdP. In our analysis, the EC 10 total values of these antiarrhythmic compounds for in vivo QT assays are similar to the ETPC total in humans. Therefore, in some cases, the EC 10 total values for in vivo QT assays can be used to evaluate the potential drug-induced QT interval prolongation without correction for plasma protein binding. However, it is generally known that a drug bound to proteins in plasma or tissue is not able to interact with its target molecules. For drugs with a different percentage of plasma protein binding in humans and animals, it is necessary to evaluate the risk using the unbound / free plasma concentration ratio.
Safety margin relative to EC 10 values
The ratios (EC 10 total / ETPC total , EC 10 unbound / ETPC unbound ) of the antiarrhythmic compounds tested were all below 6; the EC 10 total and EC 10 unbound values of these compounds were comparable to ETPC total and ETPC unbound , respectively. Furthermore, even though the ratios of the other positive compounds were less than 20, the ratio of terfenadine in anesthetized dogs was 123. Although the reason why the terfenadine ratio is greater than 100 is not clear, the time that blood was sampled for measurement of plasma drug concentrations may be involved. In anesthetized dogs, blood samples were collected at 10 min and 25 min after the start of intravenous infusion, which is thought to be different from the time at which the QT-prolongation-threshold concentration is reached.
Plasma concentrations were not measured for the negative-compound-administered animals, and thus the ratios (EC 10 total / ETPC total , EC 10 unbound / ETPC unbound ) could not be calculated. Negative compounds, except for nifedipine in the in vivo QT assays using conscious dogs, did not influence the QTc interval. Our dataset suggests that a putative margin of 20-fold between the in vivo QT assay EC 10 values and the ETPC total would be adequate to ensure the safety of drugs.
These results are consistent with the previous report that states that the safety margin and the ratios between the hERG/ I Kr assay IC 50 values and human ETPC unbound were less than 30 (6) . If the data from the in vivo QT assays as well as the hERG/ I Kr assay indicates that the ratio (EC 10 total / ETPC total or EC 10 unbound / ETPC unbound ) is less than 20, it is necessary to discuss integrated risk assessment in the Investigator's Brochure or in the "Non-clinical Overview" section of the Common Technical Documents (CTD) (7) .
The in vitro action potential assay using guinea-pig papillary muscles is not suitable for the purposes of safety margin since the ratios (EC 10 / ETPC unbound ) were far apart. Indeed, the ratios of EC 10 values of APD 90 or APD 30 -90 to ETPC unbound varied from 0.9 to hundreds of thousands (data not shown). However, this assay system is at least suitable for the evaluation of potential druginduced QT interval prolongation. Since the effects on other cardiac ion channels is also a possibility in addition to the effect on I K , the in vitro action potential assay is still considered to be a useful assay system (10, 28 (14) .
In conclusion, it is appropriate that the data from the in vivo QT assays should be considered for the evaluation of the safety margin. It is conceivable that the ratio between the in vivo QT assay EC 10 values and ETPC is a very useful index for evaluating the safety margin for drug-induced QT interval prolongation. The accuracy of the numerical value for the ratio: EC 10 total / ETPC total , EC 10 unbound / ETPC unbound , that is, the safety margin relative to EC 10 values, will increase by accumulating additional data on more compounds in our database.
